anticonvulsants/비만증

TECHNICAL FIELD The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with

TECHNICAL FIELD The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with

TECHNICAL FIELD The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with

TECHNICAL FIELD Embodiments disclosed herein generally relate to a method of treatment for weight-loss and other conditions in a mammal. More particularly, embodiments herein are directed to anatomically targeted, low-dosage delivery of antiepileptic/anticonvulsant compounds for weight-loss and

BACKGROUND OF THE INVENTION About 97 million adults in the United States are overweight or obese. The medical problems caused by overweight and obesity can be serious and often life-threatening, and include diabetes, shortness of breath, gallbladder disease, hypertension, elevated blood cholesterol

BACKGROUND OF THE INVENTION About 97 million adults in the United States are overweight or obese. The medical problems caused by overweight and obesity can be serious and often life-threatening, and include diabetes, shortness of breath, gallbladder disease, hypertension, elevated blood cholesterol

BACKGROUND OF THE INVENTION About 97 million adults in the United States are overweight or obese. The medical problems caused by overweight and obesity can be serious and often life-threatening, and include diabetes, shortness of breath, gallbladder disease, hypertension, elevated blood cholesterol

BACKGROUND OF THE INVENTION About 97 million adults in the United States are overweight or obese. The medical problems caused by overweight and obesity can be serious and often life-threatening, and include diabetes, shortness of breath, gallbladder disease, hypertension, elevated blood cholesterol

FIELD OF THE INVENTION The present invention is directed to neurotherapeutic azole compounds containing a carbamoyl group which are useful as anticonvulsant agents. DESCRIPTION OF THE PRIOR ART Many reports have disclosed that arylalkyl azole compounds are effectively used as anticonvulsant,